Executed copyAsset Purchase Agreement • January 8th, 2016 • Aralez Pharmaceuticals Inc. • Pharmaceutical preparations
Contract Type FiledJanuary 8th, 2016 Company IndustryPortions herein identified by [**] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.
Executed copyAsset Purchase Agreement • January 8th, 2016 • Aralez Pharmaceuticals Inc. • Pharmaceutical preparations
Contract Type FiledJanuary 8th, 2016 Company IndustryPortions herein identified by [**] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.
Executed copyAsset Purchase Agreement • January 8th, 2016 • Aralez Pharmaceuticals Inc. • Pharmaceutical preparations
Contract Type FiledJanuary 8th, 2016 Company IndustryPortions herein identified by [**] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.
Executed copyAsset Purchase Agreement • December 9th, 2014 • Tribute Pharmaceuticals Canada Inc. • Pharmaceutical preparations
Contract Type FiledDecember 9th, 2014 Company IndustryPortions herein identified by [**] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.